HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Drug exposure for PDA closure in France: a prospective, cohort-based, analysis

Abstract : To describe the exposure to drugs used for the treatment of patent ductus arteriosus (PDA) in a large cohort of preterm infants born before 32 weeks of gestation. METHODS: A prospective observational cohort analysis was conducted during 2 years in 28 French level 3 NICU using the same computerized order-entry system. The main outcome was "a medically treated PDA," defined as exposure to ibuprofen, indomethacin, or paracetamol prescribed with the indication of PDA closure. Secondary outcomes were as follows: time of the first treatment administration; total exposure to furosemide during hospitalization; and rate of PDA refractory to pharmacological closure. RESULTS: The study cohort consisted of 2614 infants. Among them, 474 (18.1%) received a medical treatment for PDA, with a mean postnatal age at treatment of 4.3 ± 6.6 days. The drug used as a first-line treatment was ibuprofen in 89.5% and paracetamol in 10.5%. One hundred and ninety-five infants (7.4%) had a PDA refractory to pharmacological closure. At the multivariate analysis, factors associated with PDA refractory to pharmacological closure (OR; 95% CI) were as follows: gestational age (GA) (0.81; 0.72-0.90), paracetamol as the first-line treatment (0.32; 0.15-0.68), and pharmacological treatment before 48 h of life (0.63; 0.43-0.94). 24.6% of the study cohort was exposed to furosemide (cumulative dose 6.5 ± 12.6 mg/kg). Variables significantly associated with higher cumulative doses of furosemide were lower GA and ibuprofen treatment (both p < 0.0001). CONCLUSION: Drug utilization patterns in infants with PDA vary among centers. Pharmacoepidemiology studies can provide new information on factors associated with PDA refractory to medical treatment.
Document type :
Journal articles
Complete list of metadata

Contributor : Réunion Univ Connect in order to contact the contributor
Submitted on : Wednesday, December 16, 2020 - 7:09:55 AM
Last modification on : Thursday, February 24, 2022 - 9:32:11 AM




Silvia Iacobelli, Simon Lorrain, Béatrice Gouyon, Silvia Gambacorta, Nicola Laforgia, et al.. Drug exposure for PDA closure in France: a prospective, cohort-based, analysis. European Journal of Clinical Pharmacology, Springer Verlag, 2020, 76 (12), pp.1765-1772. ⟨10.1007/s00228-020-02974-1⟩. ⟨hal-03070829⟩



Record views